Late Breaking Abstract - Inhaled indacaterol does not affect lung function or symptoms in lymphangioleiomyomatosis: a double blind placebo controlled cross-over trial

D. Yates (Sydney, NSW, Australia)

Source: International Congress 2017 – From idiopathic pulmonary fibrosis (IPF) to rare diseases
Session: From idiopathic pulmonary fibrosis (IPF) to rare diseases
Session type: Oral Presentation
Number: 4634
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Yates (Sydney, NSW, Australia). Late Breaking Abstract - Inhaled indacaterol does not affect lung function or symptoms in lymphangioleiomyomatosis: a double blind placebo controlled cross-over trial. 4634

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Late Breaking Abstract - The impact of regular bisoprolol on recovery with salbutamol in asthma; a double-blind randomised controlled trial
Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Year: 2019


Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial
Source: Virtual Congress 2021 – ALERT: bronchiectasis and COVID
Year: 2021



Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial
Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021
Year: 2021



Short-term effect of a single dose of inhaled procaterol on exercise performance in COPD: a randomized, double blind, placebo-controlled, crossover trial
Source: Annual Congress 2008 - Physiological response to exercise performance
Year: 2008


Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT?
Source: ERJ Open Res 2016: 00055-2016
Year: 2016



Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial.
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018


Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19
Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19
Year: 2021



INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015

Budesonide versus prednisone in acute wheezing: randomized double-blinded controlled placebo study
Source: Annual Congress 2008 - Treatment and outcome of childhood asthma: new perspectives
Year: 2008


Paracetamol increases airway resistance in stable asthmatics: A double blind, randomized, placebo controlled study
Source: Annual Congress 2010 - New or old physiological parameters in chronic airway disorders?
Year: 2010


A randomised double-blind placebo-controlled trial of the effect of inhaled heparin on lung function, hyperinflation and exercise capacity in patients with COPD
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016

Azithromycin for the treatment of cough in idiopathic pulmonary fibrosis: A randomized controlled cross-over pilot trial.
Source: Virtual Congress 2020 – Chronic cough: only symptom or disease?
Year: 2020




Effect of salmetrol-fluticason combination and tiotropium on clinical and physiological improvement of bronchial anthracofibrosis, a double blind randomized, cross over, placebo controlled, clinical trial.
Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology
Year: 2017


Late Breaking Abstract - Open-label trial of budesonide/formoterol reliever therapy in mild asthma
Source: International Congress 2019 – Novel findings from asthma clinical trials
Year: 2019




Airway hyperresponsiveness to mannitol as a predictor of treatment response to ciclesonide in patients with suspected asthma: A double-blind, randomised, placebo-controlled trial
Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease
Year: 2012

Late Breaking Abstract - Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia – The BESTCILIA randomized placebo-controlled trial
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Intensive care and infection
Year: 2019



Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial
Source: Eur Respir J, 51 (1) 1701926; 10.1183/13993003.01926-2017
Year: 2018



Airway clearance in bronchiectasis: a randomised crossover trial of ACBT versus TIRE
Source: Eur Respir J 2003; 22: Suppl. 45, 238s
Year: 2003

Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial
Source: Eur Respir J, 58 (1) 2100130; 10.1183/13993003.00130-2021
Year: 2021